Related Experiment Video
Updated: Aug 13, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 3, 2013
[Diagnosis and staging of metastatic hormone-sensitive prostate cancer]
Philipp Krausewitz1, Manuel Ritter2, Markus Essler3
1Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn (AöR), Venusberg-Campus 1, 53127, Bonn, Deutschland. Philipp.Krausewitz@ukbonn.de.
Background:
Risk stratification of patients with metastatic hormone-sensitive prostate cancer (mHSPC) has undergone significant changes in recent years in light of new therapies and innovative imaging.
Objectives:
Established and innovative methods for detection of metastasis, risk group stratification, and treatment of mHSPC are outlined and compared.
Materials And Methods:
Background knowledge and treatment-relevant guideline recommendations on mHSPC are presented and complemented by recent study results.
Results:
Integration of modern imaging techniques, especially prostate-specific membrane antigen (PSMA) PET/CT, into the diagnostic algorithm has the potential to significantly improve risk stratification and treatment of mHSPC. By using PSMA PET/CT, metastases are detected early and sensitively. This leads to the definition of new subgroups amenable to modern therapeutic strategies. The prognostic value of using PSMA PET/CT with regard to established risk categories in mHSPC is currently being evaluated.
Conclusions:
Modern imaging, especially PSMA PET/CT, has significant added value for the diagnosis and treatment of mHSPC in almost all subgroups. In particular, it helps to select patients who will benefit from intensification or de-escalation of systemic therapy.
